Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects

What is the purpose of this trial?

Wilson Disease (WD) is an autosomal recessive disorder of impaired copper (CU) transport caused by mutations in the ATP7B gene. WTX101 (bis-choline tetrathiomolybdate) is a first-in-class copper-protein-binding agent with a unique mechanism of action, under investigation as a novel therapy for WD. It is formulated as an enteric coated tablet (15 mg strength) for oral administration. The purpose of this study is to evaluate the efficacy of WTX101 administered for 48 weeks compared to standard of care (SOC) in WD subjects aged 18 and older.

Participation Guidelines

Ages: 18 years and older

Gender: Both

Wilson Therapeutics AB

Start Date: 04/02/2018

End Date: 12/31/2018

Last Updated: 04/13/2018

Study HIC#: 2000022372

Get Involved

For more information about this study, contact:
Sarah Swift
+1 860-372-9271

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Michael Schilsky

Principal Investigator